ME Therapeutics Holdings Inc. (METXF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$1.67 (+0.00%) as of
Key statistics
- Market cap
- 50.18M
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 1.6700 – 3.2500
- Beta
- -0.01
- Profit margin
- 0.00%
About ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Vancouver, BC, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.